Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome
NCT00789165Phase 3Withdrawn
- Sponsor
- International Registry of Asymptomatic Brugada Syndrome
- Start
- Dec 2009
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label trial of quinidine in Brugada syndrome (2 arms), sponsored by International Registry of Asymptomatic Brugada Syndrome. Primary endpoint: Combined endpoint of all cause mortality and spontaneous life-threatening arrhythmias. Planned start Dec 2009; status: withdrawn.
02
Drugs
quinidine
03
Conditions
Brugada syndrome
Beyond the preview
Go deeper on NCT00789165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789165.